Severe Eosinophilic Asthma Treatment - FASENRA (benralizumab) Subcutaneous Injection
Overview
- FASENRA is a biologic medication used as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 6 and older.
- It is not intended for the treatment of sudden breathing problems.
Key Benefits
- Reduces the occurrence of asthma attacks by up to 51%.
- Improves lung function, making breathing easier.
- Lowers daily oral steroid use by 75%.
Mechanism of Action
- FASENRA targets and removes eosinophils, a key cause of severe asthma.
- The complete mechanism of action in asthma is not fully understood.
Clinical Trials
- Demonstrated greater improvements in lung function compared to placebo.
- In a 48-week trial, FASENRA reduced severe asthma attacks by 28%.
Dosage and Administration
- Administered as a subcutaneous injection every 8 weeks after the initial three doses.
Safety Information
- Do not use if allergic to benralizumab or its ingredients.
- Possible serious side effects include allergic reactions and anaphylaxis.
- Common side effects: headache and sore throat.
Precautions
- Inform healthcare provider if taking corticosteroids or have parasitic infections.
- Discuss use if pregnant, planning to become pregnant, or breastfeeding.
Approved Use
- Maintenance treatment with other asthma medications for people 6 years and older.
- Also approved for eosinophilic granulomatosis with polyangiitis (EGPA) in adults.
Patient Support
- Offers savings and support resources, including downloadable guides and doctor finders.
- Important to not stop existing asthma treatments unless instructed by a doctor.
Contact and Additional Resources
Disclaimer: This summary is intended for educational purposes only and should be used in conjunction with advice from healthcare professionals. Always consult a healthcare provider for medical advice and treatment.